natgillin/translations-raw huggingface dataset:
Examples of symptoms that indicate a low sugar level in the brain: headaches, intense hunger, nausea, vomiting, tiredness, sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in concentration, impaired reactions, depression, confusion, speech disturbances (sometimes total loss of speech), visual disorders, trembling, paralysis, tingling sensations (paraesthesia), numbness and tingling sensations in the area of the mouth, dizziness, loss of self-control, inability to look after yourself, convulsions, loss of consciousness.
Primeri simptomov, ki nakazujejo nizek krvni sladkor v možganih,so: glavobol, huda lakota, slabost, bruhanje, utrujenost, zaspanost, motnje spanja, nemir, agresivno vedenje, motena koncentracija, poslabšane reakcije, depresija, zmedenost, motnje govora (včasih popolna izguba govora), motnje vida, tresenje, paraliza, mravljinčenje (parestezije), omrtvelost in mravljinčenje v predelu ust, omotica, izguba nadzora nad seboj, nezmožnost poskrbeti zase, krči, izguba zavesti.
Examples of symptoms that indicate a low sugar level in the brain: headaches, intense hunger, nausea, vomiting, tiredness, sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in concentration, impaired reactions, depression, confusion, speech disturbances (sometimes total loss of speech), visual disorders, trembling, paralysis, tingling sensations (paraesthesia), numbness and tingling sensations in the area of the mouth, dizziness, loss of self-control, inability to look after yourself, convulsions, loss of consciousness.
Primeri simptomov, ki nakazujejo nizek krvni sladkor v možganihso: glavobol, huda lakota, slabost, bruhanje, utrujenost, zaspanost, motnje spanja, nemir, agresivno vedenje, motena koncentracija, poslabšane reakcije, depresija, zmedenost, motnje govora (včasih popolna izguba govora), motnje vida, tresenje, paraliza, mravljinčenje (parestezije), omrtvelost in mravljinčenje v predelu ust, omotica, izguba nadzora nad seboj, nezmožnost poskrbeti zase, krči, izguba zavesti.
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast : sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat.
Primeri simptomov, ki vam povedo, da se je krvni sladkor znižal preveč ali prehitro, so: znojenje, vlažna in lepljiva koža, tesnoba, hiter srčni utrip, visok krvni tlak, razbijanje srca in nereden srčni utrip.
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat.
Primeri simptomi, ki vam povedo, da se je krvni sladkor znižal preveč ali prehitro, so: znojenje, vlažna in lepljiva koža, tesnoba, hiter srčni utrip, visok krvni tlak, razbijanje srca in nereden srčni utrip).
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat.
Primeri simptomov, ki povedo, da se je krvni sladkor znižal preveč ali prehitro: znojenje, vlažna in lepljiva koža, tesnobnost, hiter srčni utrip, visok krvni tlak, razbijanje srca (palpitacije) in nereden srčni utrip.
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat.
Primeri simptomov, ki vam povedo, da se je krvni sladkor znižal preveč ali prehitro, so : znojenje, vlažna in lepljiva koža, tesnoba, hiter srčni utrip, visok krvni tlak, razbijanje srca in nereden srčni utrip.
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat.
Primeri simptomov, ki vam povedo, da se je krvni sladkor znižal preveč ali prehitro, so: znojenje, vlažna in lepljiva koža, tesnoba, hiter srčni utrip, visok krvni tlak, palpitacije in nereden srčni utrip.
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat.
Primeri simptomov, ki vam povedo, da se je krvni sladkor znižal preveč ali prehitro, so: znojenje, vlažna in lepljiva koža, tesnoba, hiter srčni utrip, visok krvni tlak, razbijanje srca (občutek razbijanja srca) in nereden srčni utrip.
Examples of typical dose schedules based on the body weight of patients are shown in the table below:
Primeri tipičnih razporedov odmerjanja na podlagi telesne mase bolnikov so prikazani v spodnji razpredelnici:
Exanthema
eksantem
exceed 10 mg/day.
večji od 10 mg/dan.
exceed a daily dose of
Victrelis ne sme preseči
exceed a daily dose of 10 mg when
z zdravilom ZEPATIER ne sme preseči
exceed a daily dose of 20 mg when
z zdravilom ZEPATIER ne sme preseči
exceed a dose comparable to
odmerka, ekvivalentnega
exceeding a daily dose of
da bi presegli dnevni
Exceedingly rare cases of transient visual loss and myocardial ischaemia/infarction occurring during or within 2 hours of infliximab infusion have also been reported (see section 4.4).
Poročali so tudi o izredno redkih primerih prehodne izgube vida in ishemije miokarda ali miokardnega infarkta, ki so nastopili med infundiranjem ali v roku dveh ur po prejemu infuzije infliksimaba (glejte poglavje 4.4).
Except as a single dose at the recommended dose rate.
Drugače kot samo v enkratnem priporočenem odmerku.
Except for one segment II test in the rabbit, no other reproductive toxicity studies were conducted.
Razen enega testa II. segmenta pri kuncih druge študije reprodukcijske toksičnosti niso bile opravljene.
Except for Table 1, all tables will be based on number of reactions (presented on PT level, sorted by System Organ Class [SOC] and High Level Term [HLT]) and not number of cases.
Razen preglednice 1 bo v vseh preglednicah navedeno število učinkov (predstavljenih po stopnji PT in razvrščenih po organskih sistemih [SOC] in terminu visoke stopnje [HLT]) in ne število primerov.
Except for Table 1, all tables will be based on number of reactions (presented on PT level, sorted by System Organ Class [SOC] and High Level Term [HLT]) and not number of cases.
Razen preglednice 1 bodo vse preglednice temeljile na številu učinkov (predstavljeni po nivoju PT, razvrščeni po organskem sistemu [SOC] in visokonivojskem têrminu [HLT]), ne na številu primerov.
Except for Table 1, all tables will be based on number of reactions (presented on PT level, sorted by System Organ Class [SOC] and High Level Term [HLT]) and not number of cases.
Razen za tabelo 1 temeljijo vse tabele na številu učinkov (predstavljenih na ravni PI, razvrščenih po organskem sistemu [OS] in izrazu visoke ravni [HLT]), ne pa po številu primerov.
Except for the active moiety isavuconazole, no individual metabolite was observed with an AUC > 10% of total radio-labelled material.
Razen aktivne spojine, izavukonazola, ni bil opaţen noben posamezen metabolit z vrednostjo AUC > 10 % celotnega radioaktivno označenega materiala.
Except for the active moiety isavuconazole, no individual metabolite was observed with an AUC > 10% of total radio-labelled material.
Razen aktivne učinkovine izavukonazola ni bil opaţen noben posamezen metabolit z vrednostjo AUC > 10 % celotnega radioaktivno označenega materiala.
Except for the site of injection, the highest vector DNA copy numbers were found in the liver and blood.
Z izjemo mesta injiciranja so največje število kopij DNK vektorja odkrili v jetrih in krvi.
Except in emergency situations, do not use in animals suffering from diabetes mellitus, renal insufficiency, cardiac insufficiency hyperadrenocorticism, or osteoporosis.
Ne uporabite pri živalih s sladkorno boleznijo, ledvično insuficienco, srčnim popuščanjem, hiperadrenokorticizmom ali osteoporozo, razen v nujnih primerih.
Except in emergency situations, do not use in animals suffering from diabetes mellitus, renal insufficiency, cardiac insufficiency, hyperadrenocorticism, or osteoporosis.
Ne uporabite pri živalih s sladkorno boleznijo, ledvično insuficienco, srčnim popuščanjem, hiperadrenokorticizmom ali osteoporozo, razen v nujnih primerih.
Except lymphopenia (unless associated with clinical events, e.g., opportunistic infections).
z izjemo limfopenije (razen če je povezana s kliničnimi dogodki, npr. oportunističnimi okužbami)
Except where noted, data for the following selected adverse reactions are based on patients who received either ipilimumab 3 mg/kg monotherapy (n= 131) or ipilimumab 3 mg/kg in combination with gp100 (n= 380) in a Phase 3 study of advanced (unresectable or metastatic) melanoma (MDX010-20, see section 5.1).
Razen kjer ni posebej navedeno, se podatki o naslednjih izbranih neželenih učinkih nanašajo na bolnike, ki so v študiji 3. faze pri napredovalem (neoperabilnem ali metastatskem) melanomu (MDX010-20, glejte poglavje 5.1) ipilimumab prejemali v odmerku 3 mg/kg kot monoterapijo (n= 131) ali pa so ipilimumab v odmerku 3 mg/kg prejemali v kombinaciji z gp100 (n= 380).
Exception: patients with Gilbert’s syndrome who develop elevated transaminases should be managed as per the above outlined recommendations for the respective observed elevation of ALT and/or AST.
Izjema: bolnike z Gilbertovim sindromom, pri katerih so se povečale vrednosti transaminaz, je treba zdraviti po zgornjih priporočilih glede na opaženo povečanje vrednosti ALT in/ali AST.
Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4).
izjemnih primerih intersticijske pljučne bolezni, posebej pri dolgotrajnem zdravljenju (glejte
Exceptionally abortion may occur after vaccination.
Izjemoma lahko pride do abortusa po cepljenju.
Exceptionally abortion may occur after vaccination.
Po cepljenju lahko izjemoma pride do abortusa.
Exceptionally, the vaccine may be administered subcutaneously in patients with thrombocytopoenia (diminution of blood platelets) or to persons at risk of haemorrhage.
Cepivo je izjemoma mogoče dati podkožno bolnikom s trombocitopenijo (majhnim številom krvnih ploščic) ali osebam, ki jih ogrožajo krvavitve.
Exceptionally, the vaccine may be administered subcutaneously in patients with thrombocytopoenia or bleeding disorders.
Izjemoma je cepivo mogoče dati subkutano pri bolnikih s trombocitopenijo ali z motnjami hemostaze.
Exceptions where dose modifications are necessary for only one of the two treatments are detailed below for pyrexia, uveitis, RAS mutation positive non-cutaneous malignancies and QT prolongation (primarily related to dabrafenib), left ventricular ejection fraction (LVEF) reduction, retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED) and interstitial lung disease (ILD)/pneumonitis (primarily related to trametinib).
Izjeme, pri katerih je treba odmerek prilagajati samo pri enem od obeh zdravil, so navedene v nadaljevanju za primere pojava zvišane telesne temperature, uveitisa, nekožnih malignomov z mutacijo RAS, podaljšanja intervala QT (zlasti v povezavi z dabrafenibom), zmanjšanja iztisnega deleža levega prekata (LVEF), zapore mrežnične vene, odstopa mrežničnega pigmentnega epitelija in intersticijske bolezni pljuč (IBP)/pnevmonitisa (zlasti v povezavi s trametinibom).
Exceptions where dose modifications are necessary for only one of the two treatments are detailed below for pyrexia, uveitis, RAS mutation positive non-cutaneous malignancies, left ventricular ejection fraction (LVEF) reduction, retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED) and interstitial lung disease (ILD)/pneumonitis (primarily related to trametinib).
Izjeme, pri katerih je treba odmerek prilagajati samo pri enem od obeh zdravil, so navedene v nadaljevanju za primere pojava zvišane telesne temperature, uveitisa, nekožnih malignomov z mutacijo RAS, zmanjšanja iztisnega deleža levega prekata (LVEF), zapore mrežnične vene, odstopa mrežničnega pigmentnega epitelija in intersticijske bolezni pljuč (IBP)/pnevmonitisa (zlasti v povezavi s trametinibom).
Excess amount of gas in the bowels (flatulence)
povečana količina plinov v črevesju (napenjanje)
Excess body and facial hair of a male distribution pattern
povečana poraščenost po telesu in obrazu moškega tipa,
Excess fluid retention in the face and body
zadrževanje odvečne tekočine v obrazu in telesu,
Excess of fluid, usually in the legs (peripheral oedema)
preveč tekočine, običajno v nogah (periferni edem)
Excess of fluid, usually in the legs (peripheral oedema)
preveč tekočine, običajno v nogah (periferni edem),
Excess of fluid, usually in the legs (peripheral oedema)
preveč tekočine, običajno v nogah (periferni edem);
excess of triglycerides in the blood, excess of uric acid (as in gout) in the blood, increase in thyroid gland activity (which may cause nervousness, heat intolerance and excessive sweating, weight loss, palpitation, tremors),
previsoka koncentracija trigliceridov v krvi, previsoka koncentracija sečne kisline v krvi (kot pri protinu), povečano delovanje žleze ščitnice (ki lahko povzroči živčnost, neprenašanje vročine in prekomerno potenje, izguba telesne mase, razbijanje srca in tresenje),
excess of triglycerides in the blood, excess of uric acid (as in gout) in the blood, increase in thyroid gland activity (which may cause nervousness, heat intolerance and excessive sweating, weight loss, palpitation, tremors),
previsoka koncentracija trigliceridov v krvi, previsoka koncentracija sečne kisline v krvi (kot pri protinu), povečano delovanje žleze ščitnice (ki lahko povzroči živčnost, neprenašanje vročine in čezmerno potenje, hujšanje, razbijanje srca in tresenje),
excess of triglycerides in the blood, excess of uric acid (as in gout) in the blood, increase in thyroid gland activity (which may cause nervousness, heat intolerance and excessive sweating, weight loss, palpitation, tremors),
previsoka koncentracija trigliceridov v krvi, previsoka koncentracija sečne kisline v krvi (kot pri protinu, zvišana dejavnost ščitnice (kar lahko povzroči živčnost, neprenašanje vročine in pretirano znojenje, izgubo telesne mase, palpitacije, tremorje),
excess platelet production (thrombocythaemia); increased platelet counts; abnormal count in the cells in the blood that prevents bleeding (platelet count abnormal);
čezmerno nastajanje krvnih ploščic (trombocitemija), povečano število krvnih ploščic, nenormalno število krvnih celic, ki preprečujejo krvavitve (nenormalno število krvnih ploščic),
excess protein in the urine (proteinuria) rupture of the spleen
preveč beljakovin v seču (proteinurija) raztrganje vranice
excess protein in urine
prevelika količina beljakovin v urinu,
Excess volume should be expelled prior to injection.
Pred injiciranjem je treba iztisniti presežni volumen.
Excess volume to be expelled.
Presežni volumen je treba odstraniti.
Excess 13C:- Difference between pre- and post-urea sample measurements.
Presežek 13C :- Razlika med meritvami pred in po jemanju sečnine.
excessive body movements
pretirani telesni gibi
Excessive clot thickness may negatively interfere with the product’s efficacy and the wound healing process
Če je strdek predebel, lahko to negativno vpliva na učinkovitost zdravila in na proces celjenja rane.
Excessive clot thickness may negatively interfere with the product’s efficacy and the wound healing process.
Pretirana debelina strdka lahko negativno vpliva na učinkovitost zdravila in proces zdravljenja rane.
Excessive clot thickness may negatively interfere with the product’s efficacy and the wound healing process.
Če je strdek predebel, lahko to negativno vpliva na učinkovitost zdravila in na proces celjenja rane.
Excessive daytime sleepiness and suddenly falling asleep
prevelika zaspanost podnevi in nenaden nepremagljiv spanec,
Excessive daytime sleepiness and suddenly falling asleep
prevelika zaspanost podnevi in nenaden spanec,
Excessive daytime sleepiness and suddenly falling asleep
čezmerna dnevna zaspanost in nenaden spanec brez opozorila
Excessive decreases in blood pressure or respiratory depression may be corrected by decreasing or discontinuing the inspired concentration of sevoflurane.
Čezmerno znižanje krvnega tlaka ali depresijo dihanja lahko popravimo tako, da znižamo vdihano koncentracijo sevoflurana ali ga prenehamo dajati..
excessive drinking of water
pretirano pitje vode
excessive gambling,
pretirano hazardiranje,
excessive gas in stomach or intestines
napihnjenost v želodcu ali črevesju,
excessive growth of hair nail disorders, for example inflammation of the nail bed
prekomerna rast dlak bolezni nohtov, na primer vnetje podnohtja
excessive hair growth
prekomerna rast dlak
Excessive hair growth can result from serious underlying disorders (e.g. polycystic ovary syndrome, androgen secreting neoplasm) or certain active substances (e.g. cyclosporin, glucocorticoids, minoxidil, phenobarbitone, phenytoin, combined oestrogen-androgen hormone replacement therapy).
Prekomerna poraščenost je lahko posledica nekaterih resnih obolenj (kot npr. sindrom policističnih ovarijev, neoplazme, ki izločajo androgene) ali jemanja nekaterih zdravilnih učinkovin (npr. ciklosporin, glukokortikoidi, minoksidil, fenobarbiton, fenitoin, kombinirana estrogenska- androgenska hormonska nadomestna terapija).
Excessive hypotension was seen in 0.4 % of patients with uncomplicated hypertension treated with amlodipine/valsartan in placebo-controlled studies.
V študijah, kontroliranih s placebom, so čezmerno hipotenzijo opažali pri 0,4% bolnikov z nezapleteno hipertenzijo, ki so dobivali amlodipin/valsartan.
Excessive hypotension was uncommonly (0.1%) seen in patients with uncomplicated hypertension treated with Rasilez alone.
Pri bolnikih s hipertenzijo brez zapletov, ki so se zdravili samo z zdravilom Rasilez, so občasno (pri 0,1 %) opažali pretirano hipotenzijo.
Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the maximum dose of Imprida HCT (10 mg/320 mg/25 mg) compared to 1.8% of valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg) patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in patients with moderate to severe uncomplicated hypertension.
V kontroliranem preskušanju pri bolnikih z zmerno do hudo nezapleteno hipertenzijo so čezmerno hipotenzijo, vključno z ortostatsko hipotenzijo, opažali pri 1,7 % bolnikov, ki so prejemali najvišji odmerek zdravila Imprida HCT (10 mg/320 mg/25 mg), v primerjavi z 1,8 % bolnikov, ki so prejemali valsartan/hidroklorotiazid (320 mg/25 mg), z 0,4 % bolnikov, ki so prejemali amlodipin/valsartan (10 mg/320 mg), in z 0,2 % bolnikov, ki so prejemali hidroklorotiazid/amlodipin (25 mg/10 mg).
Excessive loss of body water (dehydration)
prevelika izguba vode iz telesa (dehidracija);
excessive muscle stiffness (spasticity) excessively slow or shallow breathing (respiratory depression) and/or turning blue.
prekomerno otrdelost mišic (spastičnost); prepočasno ali plitko dihanje (respiratorno depresijo) in/ali pomodrelost.
Excessive production of saliva
pretirano izločanje sline,
Excessive shaking may aggregate lipegfilgrastim, rendering it biologically inactive.
Pretirano stresanje lahko povzroči agregacijo lipegfilgrastima, ki postane biološko neaktiven.
excessive sleepiness
pretirana zaspanost
excessive sweating
prekomerno potenje
Excessive sweating
prekomerno znojenje
excessive sweating
prekomerno znojenje,
excessive sweating
pretirano znojenje
excessive sweating
čezmerno potenje
excessive sweating
čezmerno potenje,
excessive sweating
čezmerno znojenje
excessive sweating
čezmerno znojenje,
Excessive sweating (hyperhidrosis)
čezmerno potenje (hiperhidroza);
Excessive sweating (including night sweats)
prekomerno znojenje (vključno z nočnim potenjem)
excessive sweating (including night sweats), rash
čezmerno potenje (z nočnim znojenjem vred), izpuščaj
excessive sweating kidney stones.
čezmerno znojenje, ledvični kamni.
excessive sweating,
prekomerno potenje.
Excessive sweating, itching Feeling swollen or bloated
pretirano potenje, srbenje;
excessive sweating, itching, dry skin, swelling of the face and/or throat;
prekomerno potenje, srbenje, suha koža, otekanje obraza in/ali žrela
Excessive tear flow.
prekomerno solzenje
excessive thirst
huda žeja
excessive thirst
prekomerna žeja
excessive thirst
prekomerna žeja,
Excessive thirst
čezmerna žeja
Excessive thirst (Polydipsia)
Pretirana žeja (polidipsija)
excessive thirst,
prekomerna žeja,
Excessive thirst, high urine output, increased appetite with weight loss, tiredness (signs of diabetes)
huda žeja, povečano izločanje urina, povečan apetit s hujšanjem, utrujenost (znaki sladkorne bolezni)
excessive thirst, high urine output, increased appetite with weight loss, tiredness (signs of high level of sugar in the blood)
prekomerna žeja, izločanje velikih količin urina, povečan apetit z izgubo telesne teže, utrujenost (znaki visoke koncentracije sladkorja v krvi)
excessive use of alcohol or addiction to cocaine or stimulants
čezmerno uživanje alkohola ali zasvojenost s kokainom ali stimulansi;
excessive whitening (pallor) where the gel is applied skin redness, burning feeling of the skin or itching
prekomerno bledenje (bledica) na mestu nanosa gela rdečina kože, občutek skelenja na koži ali srbenje
Excipient
Pomožna snov
Excipient related considerations
Obravnava pomožnih snovi
Excipient related considerations
Opomba o pomožnih snoveh
Excipient related considerations
Podatki glede pomožnih snovi
Excipient related considerations
Pomožne snovi
Excipient related considerations
Upoštevanje pomožnih snovi
Excipient related considerations (sodium content)
Smernice glede pomožnih snovi (vsebnost natrija)
Excipient related warnings
Opozorila v zvezi s pomožnimi snovmi
Excipient with known effect
Pomožna(e) snov(i) z znanim učinkom
Excipient with known effect mg aspartame (E 951) and 0.075 mg lactose per orodispersible tablet
Pomožna(e) snov(i) z znanim učinkom: mg aspartama (E 951) in 0,075 mg laktoze na orodisperzibilno tableto
Excipient with known effect mg aspartame (E 951) and 0.1125 mg lactose per orodispersible tablet
Pomožna(e) snov(i) z znanim učinkom: mg aspartama (E 951) in 0,1125 mg laktoze na orodisperzibilno tableto
Excipient with known effect:
Pomožna snov z znanimi učinki:
Excipient with known effect:
Pomožnae snovi z znanim učinkom:
Excipient with known effect:
Pomožne snovi z znanim učinkom
Excipient with known effect: 0.11 mg sodium per sachet.
Pomožna snov z znanim učinkom: 0,11 mg natrija v vsaki vrečki.
Excipient with known effect: 0.16 mg sodium per capsule.
Pomožna snov z znanim učinkom: 0,16 mg natrija v vsaki kapsuli.
Excipient with known effect: 0.22 mg sodium per sachet.
Pomožna snov z znanim učinkom: 0,22 mg natrija v vsaki vrečki.
Excipient with known effect: 0.32 mg sodium per capsule.
Pomožna snov z znanim učinkom: 0,32 mg natrija v vsaki kapsuli.
Excipient with known effect: 63.91 mg lactose monohydrate
Pomožna snov z znanim učinkom: 63,91 mg laktoze monohidrata.
Excipient with known effect: Benzyl alcohol (10 mg/ 1 ml) For the full list of excipients, see section 6.1.
Pomožna snov z znanim učinkom: benzilalkohol (10 mg/1 ml) Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Excipient with known effect: each film coated tablet contains 20 mg lactose monohydrate
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 20 mg laktoze monohidrat.
Excipient with known effect: each film coated tablet contains 40 mg lactose monohydrate
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 40 mg laktoze monohidrat.
Excipient with known effect: each film coated tablet contains80 mg lactose monohydrate
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 80 mg laktoze monohidrat.
Excipient with known effect: Each film-coated tablet contains 0.06 mg colouring agent tartrazine (E102).
Pomožna snov z znanim učinkom: Ena filmsko obložena tableta vsebuje 0,06 mg barvila tartrazin (E102).
Excipient with known effect: Each film-coated tablet contains 1.82 mg lactose as monohydrate.
Pomožne snovi z znanim učinkom: Ena filmsko obložena tableta vsebuje 1,82 mg laktoze v obliki monohidrata.